Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MeCOSar-trastuzumab
- Development stage
- Preclinical
- Lead developer
- Clarity Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MeCOSar-trastuzumab (also known as SAR-trastuzumab) is a targeted copper theranostic (TCT) radiopharmaceutical being developed by Clarity Pharmaceuticals in collaboration with the University of Melbourne. It consists of the HER2-targeting monoclonal antibody trastuzumab conjugated to Clarity's proprietary sarcophagine-based bifunctional chelator, MeCOSar. MeCOSar-trastuzumab can be radiolabeled with copper-64 ([64Cu]Cu-MeCOSar-trastuzumab) for positron emission tomography (PET) imaging, or with copper-67 ([67Cu]Cu-MeCOSar-trastuzumab) for targeted beta-emitting radioimmunotherapy (RIT). The asset is being developed for the diagnosis and treatment of HER2-positive cancers, primarily breast cancer.
- Other names
- 64Cu-MeCOSar-trastuzumab67Cu-MeCOSar-trastuzumab[64Cu]Cu-MeCOSar-trastuzumab[64Cu]CuSar-trastuzumab[67Cu]Cu-MeCOSar-trastuzumab[67Cu]CuSar-trastuzumabSar-trastuzumabcopper-64 MeCOSar-trastuzumabcopper64 MeCOSar-trastuzumabcopper 64 MeCOSar-trastuzumabcopper-67 MeCOSar-trastuzumabcopper67 MeCOSar-trastuzumabcopper 67 MeCOSar-trastuzumab
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MeCOSar-trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MeCOSar-trastuzumab.